A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults.

Trial Profile

A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Staphylococcus aureus vaccine (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 May 2011 Results were presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 27th International Congress of Chemotherapy (ICC).
    • 21 Sep 2010 Planned end date changed from 1 Jan 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top